Last update 01 Nov 2024

Ming Ri Yang Guang Yao Ye Gong Si

Company|
China

Overview

Tags

Digestive System Disorders
Neoplasms
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Monoclonal antibody1
Top 5 TargetCount
LAG3(Lymphocyte activation gene 3 protein)1

Related

1
Drugs associated with Ming Ri Yang Guang Yao Ye Gong Si
TQB-2223
Target
LAG3
Mechanism
LAG3 inhibitors
Active Org.
Ming Ri Yang Guang Yao Ye Gong Si [+3]
Originator Org.
Symphogen A/SSymphogen A/S
Active Indication
Solid tumor [+4]
Inactive Indication
Advanced Malignant Solid Neoplasm [+1]
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Ming Ri Yang Guang Yao Ye Gong Si
CTR20234086 / RecruitingPhase 1
评估TQB2223注射液联合派安普利单抗注射液治疗晚期肝细胞癌的有效性和安全性Ib期临床研究
[Translation] Phase Ib clinical study to evaluate the efficacy and safety of TQB2223 injection combined with penpulimab injection in the treatment of advanced hepatocellular carcinoma
100 Clinical Results associated with Ming Ri Yang Guang Yao Ye Gong Si
Login to view more data
0 Patents (Medical) associated with Ming Ri Yang Guang Yao Ye Gong Si
Login to view more data
100 Deals associated with Ming Ri Yang Guang Yao Ye Gong Si
Login to view more data
100 Translational Medicine associated with Ming Ri Yang Guang Yao Ye Gong Si
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
TQB-2223
 ( LAG3 )		Advanced Hepatocellular Carcinoma
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free